Patent landscape for discovery of promising acyltransferase DGAT and MGAT inhibitors

References

• National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Food and Nutrition Board; Roundtable on Obesity Solutions; Callahan EA, editor. Current status and response to the global obesity pandemic: proceedings of a workshop. Washington (DC): National Academies Press (US); 2019 Jun 25. Global Trends in Obesity. Available from: https://www.ncbi.nlm.nih.gov/books/NBK544130/
   Google Scholar
• World Health Organization (WHO). Factsheet-obesity and overweight. Available from: https://www.who.int/en/news-room/fact-sheets/detail/obesity-and-overweight
   Google Scholar
• Unger RH, Clark GO, Scherer PE, et al. Lipid homeostasis, lipotoxicity and the metabolic syndrome. Biochim Biophys Acta. 2010;1801:209–214.
   PubMed Web of Science ®Google Scholar
• Ogunbode AM, Fatiregun AA, Ogunbode OO. Health risks of obesity. Ann Ib Postgrad Med. 2009;7:22–25.
   PubMedGoogle Scholar
• Van Herpen NA, Schrauwen-Hinderling VB. Lipid accumulation in non-adipose tissue and lipotoxicity. Physiol Behav. 2008;94(2):231–241.
   PubMed Web of Science ®Google Scholar
• Yen CL, Stone SJ, Koliwad S, et al. Thematic review series: glycerolipids. DGAT enzymes and triacylglycerol biosynthesis. J Lipid Res. 2008;49(11):2283–2301.
   PubMed Web of Science ®Google Scholar
• Bhatt-Wessel B, Jordan TW, Miller JH, et al. Role of DGAT enzymes in triacylglycerol metabolism. Arch Biochem Biophys. 2018;655:1–11.
   PubMed Web of Science ®Google Scholar
• Roe ND, Handzlik MK, Li T, et al. The role of diacylglycerol acyltransferase (DGAT) 1 and 2 in cardiac metabolism and function. Sci Rep. 2018;8:4983.
   Web of Science ®Google Scholar
• Chen HC, Stone SJ, Zhou P, et al. Dissociation of obesity and impaired glucose disposal in mice overexpressing acyl coenzyme A: diacylglycerolacyltransferase 1 in white adipose tissue. Diabetes. 2002;51(11):3189–3195.
   PubMed Web of Science ®Google Scholar
• Stone SJ, Myers HM, Watkins SM, et al. Lipopenia and skin barrier abnormalities in DGAT2-deficient mice. J Biol Chem. 2004;279:11767–11776.
   PubMed Web of Science ®Google Scholar
• Cases S, Stone SJ, Zhou P, et al. Cloning of DGAT2, a second mammalian diacylglycerol acyltransferase, and related family members. J Biol Chem. 2001;276(42):38870–38876.
   PubMed Web of Science ®Google Scholar
• Liu Y, Millar JS, Cromley DA, et al. Knockdown of acyl-CoA: diacylglycerolacyltransferase 2 with antisense oligonucleotide reduces VLDL TG and ApoB secretion in mice. Biochim Biophys Acta. 2008;1781(3):97–104.
   PubMed Web of Science ®Google Scholar
• Yu XX, Murray SF, Pandey SK, et al. Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice. Hepatology. 2005;42:362-371.
   Web of Science ®Google Scholar
• Choi CS, Savage DB, Kulkarni A, et al. Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance. J Bio Chem. 2007;282:22678-22688.
   Web of Science ®Google Scholar
• Cao J, Lockwood J, Burn P, et al. Cloning and functional characterization of a mouse intestinal acyl-CoA: monoacylglycerolacyltransferase, MGAT2. J Biol Chem. 2003;278:13860–13866.
   PubMed Web of Science ®Google Scholar
• Cheng D, Nelson TC, Chen J, et al. Identification of acyl coenzyme A: monoacylglycerol acyltransferase 3, an intestinal specific enzyme implicated in dietary fat absorption. J Biol Chem. 2003;278:13611–13614.
   PubMed Web of Science ®Google Scholar
• Yen CL, Farese RV Jr. MGAT2, a monoacylglycerol acyltransferase expressed in the small intestine. J Biol Chem. 2003;278:18532–18537.
   PubMed Web of Science ®Google Scholar
• Yen CL, Cheong ML, Grueter C, et al. Deficiency of the intestinal enzyme acyl CoA: monoacylglycerolacyltransferase-2 protects mice from metabolic disorders induced by high-fat feeding. Nat Med. 2009;15:442–446.
   PubMed Web of Science ®Google Scholar
• Hubbard BK, Enyedy I, Gilmore TA, et al. Antisense and small-molecule modulation of diacylglycerol acyltransferase. Expert Opin Ther Patents. 2007;17(11):1331–1339.
   Web of Science ®Google Scholar
• King AJ, Judd AS, Souers AJ. Inhibitors of diacylglycerol acyltransferase: a review of 2008 patents. Expert Opin Ther Patents. 2010;20(1):20–29.
   Web of Science ®Google Scholar
• Naik R, Obiang-Obounou BW, Kim M, et al. Therapeutic strategies for metabolic diseases: small molecule diacylglycerol acetyltransferase (DGAT) inhibitors. ChemMedChem. 2014;9:2410–2424.
   PubMed Web of Science ®Google Scholar
• Devasthale P, Cheng D. Monoacylglycerol acyltransferase 2 (MGAT2) inhibitors for the treatment of metabolic diseases and nonalcoholic steatohepatitis (NASH). J Med Chem. 2018;61(22):9879–9888.
   PubMed Web of Science ®Google Scholar
• Ohshiro T, Tomoda H. Acyltransferase inhibitors: a patent review (2010–present). Expert Opin Ther Patents. 2014;25(2):1–14.
   PubMed Web of Science ®Google Scholar
• Metabasis Therapeutics, Inc. Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof. United States patent US9340566B2. 2016.
   Google Scholar
• GlaxoSmithKline LLC. Compounds as diacylglycerol acyltransferase inhibitors. United States patent US10174049B2. 2019.
   Google Scholar
• GlaxoSmithKline LLC. Compounds as diacylglycerol acyltransferase inhibitors. United States patent US9624174B2. 2017.
   Google Scholar
• Glaxosmithkline Intellectual Property (No.2) Ltd. Compounds as diacylglycerol acyltransferase inhibitors. United States patent US9040517B2. 2015.
   Google Scholar
• Glaxosmithkline Intellectual Property (No.2) Ltd. Compounds as diacylglycerol acyltransferase inhibitors. United States patent US9242929B2. 2016.
   Google Scholar
• Janssen Pharmaceutica NV. Drug combinations comprising a DGAT inhibitor and a PPAR-agonist. United States patent US2018028660A1. 2018.
   Google Scholar
• Medshine Discovery Inc.; Qingdao Huanghai Pharmaceutical Co., Ltd. DGAT1 inhibitor and preparation method and use thereof. United States patent US9809604B2. 2017.
   Google Scholar
• Novartis AG. Cyclic bridgehead ether DGAT1 inhibitors. United States patent US2015166563A1. 2015.
   Google Scholar
• Novartis AG. Cyclic ether DGAT1 inhibitors. United States patent US9108956B2. 2015.
   Google Scholar
• Novartis AG. Cyclic bridgehead ether DGAT1 inhibitors. JP6042529B2. 2016.
   Google Scholar
• Kainos Medicine, Inc. Compounds as inhibitors of diacylglycerol O-acyltransferase type 1 enzyme. United States patent US9271969B2. 2016.
   Google Scholar
• Intervet Inc.; Intervet International B.V. Pyridine derivatives as DGAT-1 inhibitors. WO2014140241A1. 2014.
   Google Scholar
• DeVita et al. Imidazole derivatives. United States patent US2014088124A1. 2014.
   Google Scholar
• Pfizer Inc. Diacylglycerol acyl transferase 2 inhibitors. United States patent US20180258081A1. 2018.
   Google Scholar
• Pfizer Inc. Diacylglycerol acyl transferase 2 inhibitors. United States patent US10188653B2. 2019.
   Google Scholar
• Pfizer Inc. Diacylglycerol acyl transferase 2 inhibitors. United States patent US9296745B2. 2016.
   Google Scholar
• Merck Sharp & Dohme Corp. Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2. United States patent US9877957B2. 2018.
   Google Scholar
• Merck Sharp & Dohme Corp. Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2. United States patent US10568876B2. 2020.
   Google Scholar
• Merck Sharp & Dohme Corp. Isoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2. United States patent US9828369B2. 2017.
   Google Scholar
• Merck Sharp & Dohme Corp. Isoquinoline derivatives useful as inhibitors of diacylglyceride O-Acyltransferase 2. United States patent US2017275274A1. 2017.
   Google Scholar
• Merck Sharp & Dohme Corp. Indazole derivatives useful as inhibitors of diacylglyceride O-Acyltransferase 2. WO2018093696A1. 2018.
   Google Scholar
• Merck Sharp & Dohme Corp. Indole derivatives useful as inhibitors of diacylglyceride O-Acyltransferase 2. WO2018093698A1. 2018.
   Google Scholar
• Korea Research Institute of Bioscience and Biotechnology. Novel azaindole compounds for inhibiting diacylglycerol acyltransferase 2 and use thereof. KR101596123B1. 2016.
   Google Scholar
• Dainippon Sumitomo Pharma Co. Ltd. Pharmaceutical composition containing bicyclic pyrimidine derivative. JP2014005245A. 2014.
   Google Scholar
• Dainippon Sumitomo Pharma Co. Ltd. Bicyclic pyrimidine compound. JP2014009165A. 2014.
   Google Scholar
• Taisho Pharmaceutical Co., Ltd. Nitrogen-containing condensed heterocyclic compound. EP2687507A1. 2014.
   Google Scholar
• Eli Lilly and Company. Morpholinyl derivatives useful as MOGAT-2 inhibitors. United States patent US8993568B2. 2015.
   Google Scholar
• Ajinomoto Co., Inc. Novel tetrahydropyridopyrimidinone derivative. United States patent US2015368242A1. 2015.
   Google Scholar
• Dainippon Sumitomo Pharma Co. Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the compound. WO2008038768A1. 2008.
   Google Scholar
• Ajinomoto Co., Inc. Novel tetrahydropyrido pyrimidinone derivative. WO2015129845A1. 2015.
   Google Scholar
• Takeda Pharmaceutical. Sulfonamide compound. WO2016121782A1. 2016.
   Google Scholar
• Shionogi & Co., Ltd. Non-aromatic heterocyclic derivative having MGAT2 inhibitory activity. United States patent US10335401B2. 2019.
   Google Scholar
• Shionogi & Co., Ltd. Non-aromatic heterocyclic derivative having MGAT2 inhibitory activity. EP3395798A1. 2018.
   Google Scholar
• Shionogi & Co., Ltd. Dihydropyridone derivative having MGAT2 inhibitory activity. WO2018235785A1. 2018.
   Google Scholar
• Shionogi & Co., Ltd. Fused ring derivative having MGAT-2 inhibitory activity. WO2019013311A1. 2019.
   Google Scholar
• Shionogi & Co., Ltd. Fused ring derivative having MGAT-2 inhibitory activity. WO2019013312A1. 2019.
   Google Scholar
• Shionogi & Co., Ltd. Spiro heterocyclic derivative having MGAT2 inhibiting activity. WO2017069224A1. 2017.
   Google Scholar
• Bristol-Myers Squibb Company. Substituted pyridinones as MGAT2 inhibitors. United States patent US9974778B2. 2018.
   Google Scholar
• Bristol-Myers Squibb Company. Tetrazolone-substituted dihydropyridinone MGAT2 inhibitors. United States patent US9896431B2. 2018.
   Google Scholar
• Bristol-Myers Squibb Company. Aryl dihydropyridinones and piperidinone MGAT2 inhibitors. United States patent US10369140B2. 2019.
   Google Scholar
• Bristol-Myers Squibb Company. Dihydropyridinone MGAT2 inhibitors. United States patent US9856244B2. 2018.
   Google Scholar
• Bristol-Myers Squibb Company. Dihydropyridinone MGAT2 inhibitors. United States patent US9822074B2. 2017.
   Google Scholar
• Bristol-Myers Squibb Company. Aryl dihydropyridinones and piperidinones as MGAT2 inhibitors. EP3053912B1. 2018.
   Google Scholar
• Merck Sharp & Dohme Corp. Isoquinoline derivatives as MGAT2 inhibitors. United States patent US2018009796A1. 2018.
   Google Scholar
• Libby P. The forgotten majority: unfinished business in cardiovascular risk reduction. J Am Coll Cardiol. 2005;46:1225–1228.
   PubMed Web of Science ®Google Scholar
• Armitage J, Bowman L, Wallendszus K, et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet. 2010;376:1658–1669.
   PubMed Web of Science ®Google Scholar
• Egan A, Colman E. Weighing the benefits of high-dose simvastatin against the risk of myopathy. N Engl J Med. 2011;365:285–287.
   PubMed Web of Science ®Google Scholar
• Raal FJ, Pilcher GJ, Illingworth DR, et al. Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia. Atherosclerosis. 1997;135:249–256.
   PubMed Web of Science ®Google Scholar
• Verd JC, Peris C, Alegret M, et al. Different effect of simvastatin and atorvastatin on key enzymes involved in VLDL synthesis and catabolism in high fat/cholesterol fed rabbits. Br J Pharmacol. 1999;127:1479–1485.
   PubMed Web of Science ®Google Scholar
• Dow RL, Li J-C, Pence MP, et al. Discovery of PF-04620110, a potent, selective, and orally bioavailable inhibitor of DGAT-1. ACS Med Chem Lett. 2011;2:407–412.
   PubMed Web of Science ®Google Scholar
• Barlind JG, Bauer UA, Birch AM, et al. Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). J Med Chem. 2012;55:10610–10629.
   PubMed Web of Science ®Google Scholar
• Zhao G, Souers AJ, Voorbach M, et al. Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor. J Med Chem. 2008;51:380–383.
   PubMed Web of Science ®Google Scholar
• Nakajima K, Chatelain R, Clairmont KB, et al. Discovery of an orally bioavailable benzimidazole diacylglycerol acyltransferase 1 (DGAT1) inhibitor that suppresses body weight gain in diet-induced obese dogs and postprandial triglycerides in humans. J Med Chem. 2017;60:4657–4664.
   PubMed Web of Science ®Google Scholar
• Birch AM, Birtles S, Buckett LK, et al. Discovery of a potent, selective, and orally efficacious pyrimidinooxazinyl bicyclooctaneacetic acid diacylglycerol acyltransferase-1 inhibitor. J Med Chem. 2009;52:1558-1568.
   Web of Science ®Google Scholar
• Denison H, Nilsson C, Lofgren L, et al. Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial. Diabetes Obes Metab. 2014;16(4):334–343.
   PubMed Web of Science ®Google Scholar
• Maciejewski BS, LaPerle JL, Chen D, et al. Pharmacological inhibition to examine the role of DGAT1 in dietary lipid absorption in rodents and humans. Am J Physiol Gastrointest Liver Physiol. 2013;304(11):G958–G969.
   PubMed Web of Science ®Google Scholar
• Haas JT, Winter HS, Lim E, et al. DGAT1 mutation is linked to a congenital diarrheal disorder. J Clin Invest. 2012;122:4680–4684.
   PubMed Web of Science ®Google Scholar
• Patil RB, Barbosa EG, Sangshetti JN, et al. LQTA-R: a new 3D-QSAR methodology applied to a set of DGAT1 inhibitors. Comput Biol Chem. 2018;74:123–131.
   PubMed Web of Science ®Google Scholar
• Zambre VP, Hambarde VA, Petkar NN, et al. Structural investigations by in silico modeling for designing NR2B subunit selective NMDA receptor antagonists. RSC Adv. 2015;5:23922–23940.
   Web of Science ®Google Scholar
• Zambre VP, Patil RB, Sangshetti JN, et al. Comprehensive QSAR studies reveal structural insights into the NR2B subtype selective benzazepine derivatives as N-Methyl-d-Aspartate receptor antagonists. J Mol Struct. 2019;1197:617–627.
   Web of Science ®Google Scholar